Literature DB >> 26547584

Down-regulation of succinate dehydrogenase subunit B and up-regulation of pyruvate dehydrogenase kinase 1 predicts poor prognosis in recurrent nasopharyngeal carcinoma.

ZhiJian Dai1, Shenhua Pan2, Congxi Chen1, Longhe Cao1, Xianhui Li1, Xiaofeng Chen1, Xiaoqing Su1, Sen Lin3.   

Abstract

Succinate dehydrogenase subunit B (SDHB) and pyruvate dehydrogenase kinase 1 (PDK1) play key roles in the regulation of growth and survival of various cancers. This study aimed to investigate expression of SDHB and PDK1 in recurrent nasopharyngeal carcinoma (rNPC) tissues and analyzed the association of SDHB and PDK1 expression with the clinical significance and potential prognostic implication of rNPC. Immunohistochemistry was performed to determine the expression of SDHB and PDK1 in tissues in primary NPC (pNPC) and rNPC patients. Our results revealed that expression of SDHB in rNPC was significantly lower than that in pNPC, while the expression of PDK1 was higher compared to pNPC. The expression levels of SDHB and PDK1 were associated with T stage, N stage, clinical stage, and metastasis of rNPC. Survival analysis showed that patients with low SDHB expression had a significantly shorter overall survival time than those with high SDHB expression. Patients with high PDK1 expression had a shorter survival time than patients with low PDK1 expression. Multivariate analysis showed that the expression of SDHB and PDK1 was an independent predictor for the survival of patients with rNPC. Our results demonstrated that down-regulation of SDHB and up-regulation of PDK1 may be novel biomarkers for predicting advanced tumor progression and unfavorable prognosis in rNPC patients.

Entities:  

Keywords:  Nasopharyngeal carcinoma; Prognosis; Pyruvate dehydrogenase kinase 1; Recurrent; Succinate dehydrogenase subunit B

Mesh:

Substances:

Year:  2015        PMID: 26547584     DOI: 10.1007/s13277-015-4107-6

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  32 in total

1.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

2.  Renal tumors associated with germline SDHB mutation show distinctive morphology.

Authors:  Anthony J Gill; Nicholas S Pachter; Angela Chou; Barbara Young; Adele Clarkson; Katherine M Tucker; Ingrid M Winship; Peter Earls; Diana E Benn; Bruce G Robinson; Stewart Fleming; Roderick J Clifton-Bligh
Journal:  Am J Surg Pathol       Date:  2011-10       Impact factor: 6.394

3.  No mutations but an increased frequency of SDHx polymorphisms in patients with sporadic and familial medullary thyroid carcinoma.

Authors:  M Montani; A M Schmitt; S Schmid; T Locher; P Saremaslani; P U Heitz; P Komminoth; A Perren
Journal:  Endocr Relat Cancer       Date:  2005-12       Impact factor: 5.678

Review 4.  Patterns of regional lymph node metastasis of nasopharyngeal carcinoma: a meta-analysis of clinical evidence.

Authors:  Francis C H Ho; Ivan W K Tham; Arul Earnest; Khai Mun Lee; Jiade J Lu
Journal:  BMC Cancer       Date:  2012-03-21       Impact factor: 4.430

5.  MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta.

Authors:  Yoshiyuki Tsukamoto; Chisato Nakada; Tsuyoshi Noguchi; Masato Tanigawa; Lam Tung Nguyen; Tomohisa Uchida; Naoki Hijiya; Keiko Matsuura; Toshio Fujioka; Masao Seto; Masatsugu Moriyama
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

6.  Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice.

Authors:  Jose R Bayascas; Nick R Leslie; Ramon Parsons; Stewart Fleming; Dario R Alessi
Journal:  Curr Biol       Date:  2005-10-25       Impact factor: 10.834

7.  Epigenetic silencing of microRNA-375 regulates PDK1 expression in esophageal cancer.

Authors:  Xiaoli Li; Rui Lin; Jiansheng Li
Journal:  Dig Dis Sci       Date:  2011-04-30       Impact factor: 3.199

8.  PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma.

Authors:  Mary T Galgano; Mark Conaway; Adam M Spencer; Bryce M Paschal; Henry F Frierson
Journal:  Hum Pathol       Date:  2009-05-07       Impact factor: 3.466

9.  Loss of the SdhB, but Not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis.

Authors:  Robert D Guzy; Bhumika Sharma; Eric Bell; Navdeep S Chandel; Paul T Schumacker
Journal:  Mol Cell Biol       Date:  2007-10-29       Impact factor: 4.272

10.  An immunohistochemical perspective of PPAR beta and one of its putative targets PDK1 in normal ovaries, benign and malignant ovarian tumours.

Authors:  N Ahmed; C Riley; M A Quinn
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

View more
  4 in total

1.  LASS5 Interacts with SDHB and Synergistically Represses p53 and p21 Activity.

Authors:  Z Jiang; F Li; Y Wan; Z Han; W Yuan; L Cao; Y Deng; X Peng; F Chen; X Fan; X Liu; G Dai; Y Wang; Q Zeng; Y Shi; Z Zhou; Y Chen; W Xu; S Luo; S Chen; X Ye; X Mo; X Wu; Y Li
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

2.  Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma.

Authors:  Kiran K Velpula; Maheedhara R Guda; Kamlesh Sahu; Jack Tuszynski; Swapna Asuthkar; Sarah E Bach; Justin D Lathia; Andrew J Tsung
Journal:  Oncotarget       Date:  2017-05-30

3.  Identification of key pseudogenes in nasopharyngeal carcinoma based on RNA-Seq analysis.

Authors:  Xiujuan Zhang; Xiaole Song; Yuting Lai; Bijun Zhu; Jiqin Luo; Hongmeng Yu; Yiqun Yu
Journal:  BMC Cancer       Date:  2021-04-30       Impact factor: 4.430

4.  SDHB downregulation facilitates the proliferation and invasion of colorectal cancer through AMPK functions excluding those involved in the modulation of aerobic glycolysis.

Authors:  Zhiming Xiao; Shaojun Liu; Feiyan Ai; Xiong Chen; Xiayu Li; Rui Liu; Weiguo Ren; Xuemei Zhang; Peng Shu; Decai Zhang
Journal:  Exp Ther Med       Date:  2017-11-10       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.